Skip to main content

Table 1 Demographics of stage IV IBC patients

From: Immune phenotype of patients with stage IV metastatic inflammatory breast cancer

Patient ID Age at diagnosis Race IBC Subtype at diagnosis Months after diagnosis of blood collection and treatment status Overall Survival (OS)
Patient 1 42 H ERPRHer2+ Month 18
Treated
67 months
Patient 2 47 C TN
Secondary IBC
Month 12
Treated
27 months
Patient 3 55 C TN Month 20
Treated
38 months
Patient 5 49 C ERPRHer2+ Month 30
Treated
44 months*
Patient 6 66 C (J) ER+PRHer2 (became TN at month 8) Month 8
Treated
10 months (cardiac disease)
Patient 7 48 C TN Month 21
Treated
27 months
Patient 8 32 C ER+PRHer2 Month 50
Treated
105 months
Patient 9 55 A ERPRHer2+ Month 4
Treatment naive
16 months
Patient 10 62 C TN Month 32
Treated
37 months
Patient 11 61 C TN Month 13
Treated
31 months
Patient 13 43 C ER+PR+Her2+ Month 1
Treatment naive
87 months
Patient 14 44 C ERPRHer2+ Month 13
Treated
115 months
Patient 15 30 C ER+PRHer2+ Month 22
Treated
39 months
Patient 16 69 A ERPRHer2+ Month 26
Treated
37 months
  1. Age at disease onset, race, IBC subtype, time in which blood samples were collected since disease onset, and survival is indicated for each patient. All the patients had metastatic disease at the time of the blood collection and received multiple therapies with the exception of patients 9 and 13
  2. C Caucasian, TN triple-negative, A Asian, H Hispanic, J Jewish heritage
  3. *Last record available
  4. Patient was breast feeding her baby when she was diagnosed with IBC